.png){kind=small}
.png){kind=small}
BackTable / Urology / Podcast / Episode #259
Prostate Tumor Board: Risk Stratification & Treatment Strategies
with Dr. Neeraj Agarwal and Dr. Tyler Seibert
Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer.
This podcast is supported by:
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2025, September 9). Ep. 259 – Prostate Tumor Board: Risk Stratification & Treatment Strategies [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Dr. Parth Modi
Dr. Parth Modi is a urologic oncologist at the University of Chicago in Chicago, Illinois.
Dr. Neeraj Agarwal
Dr. Neeraj Agarwal is a professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.
Dr. Tyler Seibert
Dr. Tyler Seibert is a radiation oncologist and Assistant Professor in the the Division of Radiation Oncology at UC San Diego School of Medicine in San Diego, California.
Synopsis
The multidisciplinary discussion addresses clinical decision-making in active surveillance versus early intervention, the role of PSMA PET imaging in detection and treatment planning, and evolving strategies for metastatic and castration-resistant disease. They also evaluate the therapeutic potential of alpha emitters and radioligand therapies, consider the evidence behind treatment intensification and de-intensification, and explore how these approaches can be individualized to optimize patient outcomes.
Timestamps
0:00 - Introduction
1:48 - Active Surveillance in Low-Risk Prostate Cancer
7:08 - Molecular Testing and Risk Stratification
8:28 - Radiation Therapy Approaches
20:16 - PSA Recurrence and PSMA PET Scans
32:40 - The Role of ADT
37:15 - PSMA PET Scans
40:58 - Genetic Testing in High-Risk and Metastatic Prostate Cancer
46:54 - Treatment Intensification vs. De-Intensification Trials
55:59 - Castration-Resistant Prostate Cancer
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Up Next
